# CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML or HR-MDS

> **NCT07347418** · PHASE1 · NOT_YET_RECRUITING · sponsor: **University of Colorado, Denver** · enrollment: 23 (estimated)

## Conditions studied

- Refractory Acute Myeloid Leukemia (AML)
- High-risk Myelodysplastic Syndrome (MDS)
- Relapsed Acute Myeloid Leukemia (AML)
- Myelodysplastic Syndrome (MDS)/AML
- Myelodysplastic Syndrome
- AML (Acute Myeloid Leukemia)

## Interventions

- **DRUG:** CD64 CAR T Cells

## Key facts

- **NCT ID:** NCT07347418
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03
- **Primary completion:** 2029-03
- **Final completion:** 2029-12
- **Target enrollment:** 23 (ESTIMATED)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07347418

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07347418, "CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML or HR-MDS". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07347418. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*